Clinical Trials Logo

Renal Impairment clinical trials

View clinical trials related to Renal Impairment.

Filter by:
  • Enrolling by invitation  
  • Page 1

NCT ID: NCT06397872 Enrolling by invitation - Renal Impairment Clinical Trials

A Phase 1, Multi-center, Open-label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses (6 Days) of 100 mg Resmetirom in Subjects With Severe Renal Impairment and in Matched Healthy Control Subjects With Normal Renal Function

Start date: March 5, 2024
Phase: Phase 1
Study type: Interventional

The purpose of this study is to directly characterize the pharmacokinetic (PK) profiles of resmetirom and its major metabolite (MGL-3623) following oral administration of 100 mg resmetirom (QD x 6 days) in subjects with severe renal impairment (RI) compared to healthy matched control subjects with normal renal function.

NCT ID: NCT00852800 Enrolling by invitation - Renal Impairment Clinical Trials

Low-dose Albumin Solution in SBP: a Randomized Double-blind Pilot Study

ALTERNATE
Start date: March 2006
Phase: Phase 2
Study type: Interventional

Spontaneous bacterial peritonitis (SBP) is a common and severe complication of cirrhosis. The most serious complication of SBP is the hepatorenal syndrome (HRS), which occurs in up to 30 percent of patients, with high mortality. Intravenous albumin (1.5 g/kg at diagnosis and 1 g/kg 48 hours later - standard regimen) helps to prevent HRS and improves survival. No information exists on the efficacy of lower doses of albumin. This study was designed to allow direct comparison among different doses of intravenous albumin in patients with SBP - standard (SR) vs dose reduced regimen (DRR) - in order to prevent renal failure and mortality.